AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24385534 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 197
Study 23302669 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro invasive occlusion procedure
Number of subjects: 220
Study 23302669 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiopulmonary bypass surgery
Number of subjects: 220
Study 20456627 — intervention group
Group type: EXPERIMENTAL
Intervention: couple lubricants (1 lubricant for female and second lubricant for male partner)
Number of subjects: 326
Study 20456627 — intervention group
Group type: EXPERIMENTAL
Intervention: female arousal gel
Number of subjects: 326
Study 20456627 — intervention group
Group type: EXPERIMENTAL
Intervention: female lubricant
Number of subjects: 326
Study 20456627 — intervention group
Group type: COMPARATOR
Intervention: no intervention
Number of subjects: 326
Study 17972477 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-level hierarchical letter stimuli
Number of subjects: 0
Study 16336447 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg midazolam
Number of subjects: 180
Study 16336447 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg midazolam
Number of subjects: 180
Study 16336447 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.09 mg/kg midazolam
Number of subjects: 180
Study 16336447 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 180
Study 16336447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 12201618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix25 (25% insulin lispro and 75% NPL)
Number of subjects: 37
Study 9473965 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with higher fat and zinc diets
Number of subjects: 56
Study 9473965 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 9473965 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 56
Study 9473965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 56
Study 9473965 — intervention group
Group type: EXPERIMENTAL
Intervention: Original intervention
Number of subjects: 56
Study 8554280 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual inflating balloon cannula (group I)
Number of subjects: 54
Study 8554280 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inflating balloon cannula (group II)
Number of subjects: 54
Study 2677259 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0
Study 30293464 — intervention group
Group type: EXPERIMENTAL
Intervention: Internally cooled wet (ICW) electrodes
Number of subjects: 17
Study 30293464 — intervention group
Group type: EXPERIMENTAL
Intervention: Internally cooled wet (ICW) electrodes with saline infusion
Number of subjects: 17
Study 29753033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.1 mg/kg Q4W
Number of subjects: 264
Study 29753033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.5 mg/kg Q4W
Number of subjects: 264
Study 29753033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 2.0 mg/kg Q4W
Number of subjects: 264
Study 29753033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 2.0 mg/kg Q8W
Number of subjects: 264
Study 26851059 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 3000
Study 26851059 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT) insertion
Number of subjects: 3000
Study 24749682 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal encouragement during the 6-minute walk test (6MWT)
Number of subjects: 80
Study 24749682 — intervention group
Group type: COMPARATOR
Intervention: No verbal encouragement during the 6-minute walk test (6MWT)
Number of subjects: 80
Study 22512763 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-content message
Number of subjects: 2
Study 22512763 — intervention group
Group type: COMPARATOR
Intervention: Negative-content message
Number of subjects: 2
Study 19961017 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA + GA (thoracic epidural anesthesia combined with general anesthesia)
Number of subjects: 44
Study 19961017 — intervention group
Group type: COMPARATOR
Intervention: TIVA (total intravenous anesthesia)
Number of subjects: 44
Study 17980419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation with 0.5 g of docosahexaenoic acid and 0.15 g of eicosapentaenoic acid, 400 mug of methyl‐tetra‐hydrofolic acid
Number of subjects: 311
Study 17980419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation
Number of subjects: 311
Study 16202012 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Number of subjects: 6
Study 12394562 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits to patients' homes
Number of subjects: 21
Study 12394562 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 21
Study 10339805 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells
Number of subjects: 0
Study 10339805 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow graft stem cells
Number of subjects: 0
Study 8951937 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tolperisone hydrochloride
Number of subjects: 138
Study 8951937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 2009058 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-cm-margin excision
Number of subjects: 612
Study 2009058 — intervention group
Group type: COMPARATOR
Intervention: Wide excision (margins of greater than or equal to 3 cm)
Number of subjects: 612
Study 6804108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 17
Study 6804108 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 17
Study 31929122 — intervention group
Group type: EXPERIMENTAL
Intervention: Gocovri (amantadine) 274 mg once daily at bedtime
Number of subjects: 223
Study 31929122 — intervention group
Group type: EXPERIMENTAL
Intervention: Gocovri (amantadine)
Number of subjects: 223
Study 31778629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (1.5 g every 6 hours)
Number of subjects: 21
Study 29052559 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaoduqing particles 5 g thrice daily and 10 g before bedtime for 24 weeks
Number of subjects: 300
Study 29052559 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered using the same methods for 24 weeks
Number of subjects: 300
Study 26174334 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (6 weekly sessions)
Number of subjects: 209
Study 26174334 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (6 weekly sessions)
Number of subjects: 209
Study 26174334 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 209
Study 26174334 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 209
Study 26174334 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 209
Study 23137995 — intervention group
Group type: EXPERIMENTAL
Intervention: CoJet/Clearfil Ceramic Primer/Panavia F2.0/10d
Number of subjects: 15
Study 23137995 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement with CoJet
Number of subjects: 15
Study 23137995 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F2.0 with CoJet
Number of subjects: 15
Study 23137995 — intervention group
Group type: COMPARATOR
Intervention: Clearfil Esthetic Cement without CoJet
Number of subjects: 15
Study 23137995 — intervention group
Group type: COMPARATOR
Intervention: Panavia F2.0 without CoJet
Number of subjects: 15
Study 20737411 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training (CST) of nurses
Number of subjects: 89
Study 19137409 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate (Bi) infusion in dextrose water
Number of subjects: 0
Study 19137409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (AZ) with normal saline (NLS)
Number of subjects: 0
Study 19137409 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NLS) infusion alone
Number of subjects: 0
Study 17507633 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant taxane-anthracycline-containing chemotherapy and/or trastuzumab (Herceptin)
Number of subjects: 26
Study 15054078 — intervention group
Group type: COMPARATOR
Intervention: Normal-appearing pyramidal neurons from non-CD tissue
Number of subjects: 0
Study 15054078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalic neurons from CD tissue
Number of subjects: 0
Study 15054078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramidal neurons in CD tissue
Number of subjects: 0
Study 15054078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalic neurons and normal-appearing pyramidal neurons from CD tissue
Number of subjects: 0
Study 11443793 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic laser foraminoplasty
Number of subjects: 250
Study 9595988 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-14117 60 mg/d
Number of subjects: 64
Study 9595988 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-14117 120 mg/d
Number of subjects: 64
Study 9595988 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-14117 240 mg/d
Number of subjects: 64
Study 9595988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 8113252 — intervention group
Group type: EXPERIMENTAL
Intervention: Harris‐Galante acetabular component inserted without cement
Number of subjects: 21
Study 8113252 — intervention group
Group type: COMPARATOR
Intervention: Charnley acetabular component fixed with cement
Number of subjects: 21
Study 2539017 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 to 40 mg daily)
Number of subjects: 162
Study 2539017 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 to 100 mg daily)
Number of subjects: 162
Study 28986515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists
Number of subjects: 306
Study 28986515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy Technicians
Number of subjects: 306
Study 28986515 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 306
Study 26486418 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes patients with any type of diabetic retinopathy (DR) and/or maculopathy
Number of subjects: 2806
Study 26486418 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes patients with sight-threatening diabetic retinopathy
Number of subjects: 2806
Study 26486418 — intervention group
Group type: EXPERIMENTAL
Intervention: Known diabetics without regular eye examinations for DR
Number of subjects: 2806
Study 26486418 — intervention group
Group type: EXPERIMENTAL
Intervention: Known diabetics with last eye examination >24 months ago
Number of subjects: 2806
Study 26486418 — intervention group
Group type: COMPARATOR
Intervention: Hindustani individuals compared to other ethnic groups
Number of subjects: 2806
Study 23652333 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted pylorus-preserving gastrectomy (LAPPG)
Number of subjects: 292
Study 23652333 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 292
Study 23652333 — intervention group
Group type: COMPARATOR
Intervention: LADG
Number of subjects: 292
Study 23652333 — intervention group
Group type: EXPERIMENTAL
Intervention: LAPPG
Number of subjects: 292
Study 23537617 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (goserelin) for 3 months (Group 1)
Number of subjects: 80
Study 23537617 — intervention group
Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH) (Group 2)
Number of subjects: 80
Study 19691907 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg quetiapine XR
Number of subjects: 873
Study 19691907 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg quetiapine XR
Number of subjects: 873
Study 19691907 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 873
Study 19691907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 873
Study 18624596 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension label
Number of subjects: 152
Study 18624596 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication, reducing salty foods, and losing weight
Number of subjects: 152
Study 18624596 — intervention group
Group type: EXPERIMENTAL
Intervention: Low trust in physicians with unfamiliar disease label
Number of subjects: 152
Study 15780844 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine (30 mg/kg/day)
Number of subjects: 39
Study 11870242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (0.25 mg, 0.5 mg, 1 mg at three-month intervals; 4 mg as a single dose; 2 mg doses six months apart)
Number of subjects: 351
Study 11870242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 10195357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg)
Number of subjects: 27
Study 10195357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene (4 mg)
Number of subjects: 27
Study 10195357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 10195357 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (SP)
Number of subjects: 27
Study 10195357 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (CGRP)
Number of subjects: 27
Study 10195357 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-antagonists (Cetirizine and Dimethindene)
Number of subjects: 27
Study 7850984 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg/h transdermal nitroglycerin
Number of subjects: 12
Study 7850984 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 12
Study 1691125 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy only
Number of subjects: 46
Study 1691125 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy followed by endoscopic intubation
Number of subjects: 46
Study 7361087 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (500-750 mg daily)
Number of subjects: 38
Study 7361087 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (2000-3000 mg daily)
Number of subjects: 38
Study 31520045 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic two-week rule (2WR) referrals compliant with NICE NG12 guidelines
Number of subjects: 219
Study 31520045 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients seen within two weeks after referral
Number of subjects: 219
Study 31520045 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of malignancy from referrals
Number of subjects: 219
Study 27991810 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CCET (15 hours face to face)
Number of subjects: 159
Study 27991810 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact CCET (12 hours face to face)
Number of subjects: 159
Study 27991810 — intervention group
Group type: EXPERIMENTAL
Intervention: Short CCET (self-learning DVD + 8 hours face to face)
Number of subjects: 159
Study 27991810 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 159
Study 25481453 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week taper condition (N=22)
Number of subjects: 89
Study 25481453 — intervention group
Group type: EXPERIMENTAL
Intervention: H(+) participants
Number of subjects: 89
Study 25481453 — intervention group
Group type: COMPARATOR
Intervention: H(-) participants
Number of subjects: 89
Study 23404180 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) performed annually
Number of subjects: 1000
Study 23404180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CGA)
Number of subjects: 1000
Study 23404180 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA
Number of subjects: 1000
Study 20506328 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stents (DES)
Number of subjects: 1537
Study 20506328 — intervention group
Group type: COMPARATOR
Intervention: Bare Metal Stents (BMS)
Number of subjects: 1537
Study 19378676 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Express MR stent
Number of subjects: 446
Study 19378676 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Express Control stent
Number of subjects: 446
Study 17239942 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml Patent Blue diluted with 8 ml NaCl 0.9%
Number of subjects: 60
Study 17239942 — intervention group
Group type: COMPARATOR
Intervention: 4 ml Patent Blue (standard labelling volume)
Number of subjects: 60
Study 15525310 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex
Number of subjects: 52
Study 15525310 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide and eugenol (ZOE)
Number of subjects: 52
Study 12541860 — intervention group
Group type: EXPERIMENTAL
Intervention: Herba Houttuyniae irrigation liquid
Number of subjects: 192
Study 12541860 — intervention group
Group type: COMPARATOR
Intervention: Other irrigation liquids (not specified)
Number of subjects: 192
Study 9714946 — intervention group
Group type: EXPERIMENTAL
Intervention: Danger ideation reduction therapy (DIRT)
Number of subjects: 21
Study 9714946 — intervention group
Group type: COMPARATOR
Intervention: Wait list (Control)
Number of subjects: 21
Study 7992096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (CVD) plus interleukin-2 (IL-2) and interferon-alfa (IFN-alpha)
Number of subjects: 0
Study 7992096 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotherapy (IL-2 plus IFN-alpha) administered immediately after CVD
Number of subjects: 0
Study 7992096 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotherapy (IL-2 plus IFN-alpha) administered in a sandwich of biotherapy/CVD/biotherapy
Number of subjects: 0
Study 7992096 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotherapy (IL-2 plus IFN-alpha) administered concurrently with CVD
Number of subjects: 0
Study 7992096 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-based regimen with IL-2 plus IFN-alpha
Number of subjects: 0
Study 3124651 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy
Number of subjects: 48
Study 3124651 — intervention group
Group type: COMPARATOR
Intervention: Operative gastrostomy
Number of subjects: 48
Study 3124651 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (with tube replacement)
Number of subjects: 48
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental interventions reported in RCT abstracts (100%)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant eligibility criteria (#3)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison interventions (#6)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific objective or hypothesis (#7)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome (#8)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting trial results as a summary (#16)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of the study as randomized in the title (#1)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Design of the trial (#2)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial setting (#4)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization (#10)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding (#12)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Details about blinding (#13)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of participants randomized to each intervention (#14)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect size (#17)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision of the estimate of the effect (#18)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects (#19)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical significance (#25)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial registration number (#21)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Name of trial register (#22)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: How the randomization or sequence generation was done (#22)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: How allocations were concealed (#11)
Number of subjects: 198
Study 29747793 — intervention group
Group type: EXPERIMENTAL
Intervention: Source of funding for the trials (#23)
Number of subjects: 198
Study 27015572 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon triamcinolone acetonide (TA) injection
Number of subjects: 48
Study 27015572 — intervention group
Group type: COMPARATOR
Intervention: Topical nepafenac 0.1%
Number of subjects: 48
Study 25640290 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release tapentadol
Number of subjects: 666
Study 25640290 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxycodone
Number of subjects: 666
Study 23551271 — intervention group
Group type: EXPERIMENTAL
Intervention: eTIPs (electronic CBT intervention)
Number of subjects: 0
Study 23551271 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 21209411 — intervention group
Group type: EXPERIMENTAL
Intervention: AFQ056 (mGluR5 antagonist)
Number of subjects: 30
Study 21209411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21209411 — intervention group
Group type: EXPERIMENTAL
Intervention: AFQ056
Number of subjects: 30
Study 21209411 — intervention group
Group type: COMPARATOR
Intervention: AFQ056 and Placebo
Number of subjects: 30